Skip to main content

01.12.2012 | Research | Ausgabe 1/2012 Open Access

Health and Quality of Life Outcomes 1/2012

EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs

Health and Quality of Life Outcomes > Ausgabe 1/2012
Megan R Stafford, Asha Hareendran, Daisy S Ng-Mak, Ralph P Insinga, Ruifeng Xu, Donald E Stull
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7525-10-65) contains supplementary material, which is available to authorized users.

Competing interests

This study was funded by Merck Sharp & Dohme, Corp. Ralph Insinga (RPI) and Ruifeng Xu (RX) are employees of Merck Sharp & Dohme, Corp.
Daisy S. Ng-Mak (DSN) was an employee of Merck Sharp & Dohme, Corp. at the time of first submission.
Megan Stafford (MRS), Asha Hareendran (AH), and Donald Stull (DS) were employees of United BioSource Corporation and served as paid consultants to Merck Sharp & Dohme, Corp. during the conduct of this study and the development of this manuscript.

Authors’ contributions

DSN, AH, RPI, RX, and MRS have made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; MRS, AH, DSN, RPI, and RX have been involved in drafting the manuscript or revising it critically for important intellectual content; and all authors have given final approval of the version to be published. All authors read and approved the final manuscript.



To estimate utility values for different levels of migraine pain severity from a United Kingdom (UK) sample of migraineurs.


One hundred and six migraineurs completed the EQ-5D to evaluate their health status for mild, moderate and severe levels of migraine pain severity for a recent migraine attack, and for current health defined as health status within seven days post-migraine attack. Statistical tests were used to evaluate differences in mean utility scores by migraine severity.


Utility scores for each health state were significantly different from 1.0 (no problems on any EQ-5D dimension) (p < 0.0001) and one another (p < 0.0001). The lowest mean utility, − 0.20 (95% confidence interval [CI]: -0.27 – -0.13), was for severe migraine pain. The smallest difference in mean utility was between mild and moderate migraine pain (0.13) and the largest difference in mean utility was between current health (without migraine) and severe migraine pain (1.07).


Results indicate that all levels of migraine pain are associated with significantly reduced utility values. As severity worsened, utility decreased and severe migraine pain was considered a health state worse than death. Results can be used in cost-utility models examining the relative economic value of therapeutic strategies for migraine in the UK.
Authors’ original file for figure 1
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Health and Quality of Life Outcomes 1/2012 Zur Ausgabe